News Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.69 ^USD	+1.50%		+3.68%	-3.43%

Apr. 22	Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	MT
Apr. 22	Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	Apr. 22	MT
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense	Apr. 22	AQ
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	Apr. 22	CI
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team	Apr. 09	AQ
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference	Mar. 27	AQ
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic	Mar. 25	AQ
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	Mar. 25	CI
Plus Therapeutics : March 2024 Corporate Presentation	Mar. 12	PU
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases	Mar. 11	AQ
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	Mar. 11	CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	Mar. 05	AQ
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024	Feb. 27	AQ
Plus Updates Financial and Cash Guidance for 2024	Dec. 18	AQ
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses	Dec. 12	AQ
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe	Nov. 29	AQ
Transcript : Plus Therapeutics, Inc. - Special Call	Nov. 20
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar	Nov. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Summary

Filters